Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Nanomedicine and Drug Delivery Lab

Publications


Publications - 2011 to 2004

1. Rao, V.R., Prescott, E., Shelke, N., Trivedi, R., Thomas, P., Struble, C., Gadek, T., O’Neill, C.A., Kompella, U.B.* Delivery of SAR 1118 to retina via ophthalmic drops and its effectiveness in reduction of retinal leukostasis and vascular leakiness in rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest. Ophthalmol. Vis. Sci. 2010. PMID: 20445119.

2. Missel, P., Chastain, J., Mitra, A.K., Kompella, U.B., Kansara, V., Duvvuri, S., Amrite, A., and Cheruvu, N.P. In vitro transport and partitioning of AL-4940, the active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010. PMID: 20415622.

3. Mayo, A.S., Ambati, B.K., Kompella, U.B.* Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int. J. Pharm. 2009. PMID: 20025945.

4. Kadam, R.S. and Kompella, U.B.* Influence of lipophilicity on drug partitioning into sclera, choroid-RPE, retina, trabecular meshwork, and optic nerve. J. Pharmacol. Exp. Ther. 2009. PMID: 19926800.

5. Sunkara, G., Ayalasomayajula, S.P., DeRuiter, J., and Kompella, U.B.* Probenecid treatment enhances the retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine, an anionic aldose reductase inhibitor. Brain Res. Bull. 2009. PMID: 19761819.

6. Sundaram, S., Durairaj, C., Ambati, B.K., Rajagopal, R., and Kompella, U.B.* Targeted drug and gene delivery systems for lung cancer therapy. Clin. Cancer Res. 2009. PMID: 19920099.

7. Durairaj, C. and Kompella, U.B.* Dendritic polyguanidylated translocators for ocular drug delivery. Drug Del. Technol. 9(9): 36-43 (2009).

8. Barañano, D.E., Kim, S.J., Edelhauser, H.F., Durairaj, C., Kompella, U.B., and Handa, J.T. Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation, Br. J. Ophthalmol. 93(10):1387-1390 (2009). 

9. Park, K., Chen, Y., Hu, Y., Mayo, A.S., Kompella, U.B., Longeras, R., and Ma, J-x. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 58(8):1902-1913 (2009).

10. Sundaram, S., Roy, S.K., Ambati, B.K., and Kompella, U.B.* Surface functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 23(11):3752-3765 (2009).

11. Kang, S.J., Durairaj, C., Kompella, U.B., O’Brien, J.M., and Grossniklaus, H.E. Subconjunctival Nanoparticle Carboplatin in the Treatment of Murine Retinoblastoma. Arch. Ophthalmol. 127(8):1043-1047 (2009).

12. Singh, S.R. and Kompella, U.B.* Nanotechnology for gene delivery to the eye. European Ophthalmic Review. 7-11 (2009).

13. Durairaj, C., Kim, S.J., Edelhauser, H.F., Shah, J.C., and Kompella, U.B.* Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest. Ophthalmol. Vis. Sci. 50(10):4887-4897 (2009).

14. Kim, E.S., Durairaj, C., Kompella, U.B., Kadam, R.S., Lee, S.J., Mo, Y., Geroski, D.H., and Edelhauser, H.F. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulations. Pharm. Res. 26(5):1155-1161 (2009).

15. Sundaram, S., Durairaj, C., Kadam, R., and Kompella, U.B.* Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol. Cancer Ther. 8(6):1655-1665 (2009).

16. Singh, S.R., Grossniklaus, H.E., Kang, S.J., Edelhauser, H.F., Ambati, B.K., and Kompella, U.B.* Intravenous transferrin, RGD peptide, and dual targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser induced CNV. Gene Therapy 16(5):645-659 (2009).

17. Ayalasomayajula, S.P., Ashton, P., Kompella, U.B.* Fluocinolone Inhibits VEGF Expression via Glucocorticoid Receptor in Human Retinal Pigment Epithelial (ARPE)-19 Cells and TNF-?-induced Angiogenesis in Chick Chorioallantoic Membrane (CAM). J Ocul Pharmacol Ther. 25(2):97-103 (2009).

18. Kadam, R. and Kompella, U.B.* Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina and vitreous by liquid chromatography-tandem mass spectrometry. J. Chromat. B 877(3):253-260 (2009).

19. Cheruvu, N.P., Amrite, A.C., and Kompella, U.B.* Effect of diabetes on transscleral delivery of celecoxib. Pharm. Res. 26(2): 404-414 (2009).

20. Sundaram, S., Roy, S.K., Kompella, U.B.* Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides. 30(2):351-358 (2009).

21. Durairaj, C., Shah, J.C., Senapati, S., Kompella, U.B.*. Prediction of Vitreal Half-Life Based on Drug Physicochemical Properties: Quantitative Structure-Pharmacokinetic Relationships (QSPKR). Pharm. Res. 26(5):1236-1260 (2009).

22. Kratzer, A., Buchebner, M., Pfeifer, T., Becker, T.M., Uray, G., Miyazaki, M., Miyazaki-Anzai, S., Ebner, B., Chandak, P.G., Kadam, R.S., Calayir, E., Rathke, N., Ahammer, H., Radovic, B., Trauner, M., Hoefler, G., Kompella, U.B., Fauler, G., Levi, M., Levak-Frank, S., Kostner, G.M., Kratky, D. Synthetic LXR agonist attenuates plaque formation in apoE-deficient mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 50(2): 312-326 (2009).

23. Christie, J. and Kompella, U.B.*  Ophthalmic light sensitive nanocarrier systems. Drug Disc. Today 13(3-4):124-134 (2008).

24. Cheruvu, N.P.S., Amrite, A., and Kompella, U.B*. Effect of eye pigmentation on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 49(1):333-341 (2008).

25. Amrite, A. and Kompella, U.B*. Celecoxib inhibits VEGF induced proliferation of choroid-retinal endothelial cells by a Cox-2 independent mechanism. J. Pharmacol. Exp. Ther. 324(2):749-758 (2008).

26. Amrite, A., Edelhauser, H.F., and Kompella, U.B*. Modeling of corneal and retinal pharmacokinetics following periocular administration. Invest. Ophthalmol. Vis. Sci. 49(1):320-332 (2008).

27. Edelhauser HF, Boatright JH, Nickerson JM; Third ARVO/Pfizer Research Institute Working Group (Kompella-U.B., member of this group). Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 2008 Nov;49(11):4712-20.

28. Raghava, S., Goel, G., and Kompella, U.B.* Ophthalmic applications of nanotechnology. In: Ocular transporters and drug delivery. Eds: Joyce Tombran-Tink and Colin J Barnstable. Humana Press. Pages 415-435 (2008).

29. Amrite, A.C., Edelhauser, H.F., Raghava, S.R., and Kompella, U.B.* Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis.  14:150-160 (2008).

30. Yun, M., Barnett, M.E., Takemoto, D., and Kompella, U.B.* Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutates (SOD) gene. Mol. Vision 13:746-757 (2007).

31. Raghava, S. and Kompella U.B*. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: Implications for the therapy of ocular neovascular disorders. Eur. J. Pharmacol. 568(1-3):68-74 (2007).

32. Kador, P.F., Randazzo, J., Babb, T., Koushik, K., Takamura, Y., Zhu, W., Blessing, K., Kompella, U.B. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 23(2):116-123 (2007).

33. Amrite, A.C. and Kompella, U.B.* Nanoparticles and microparticles: Particle engineering, cell uptake, in vivo disposition, and efficacy. Drug Del. Technol. 7(2): 52-56 (2007).

34. Jani, P.D., Singh, N., Jenkins, C., Raghava, S., Yun, M., Amin, S., Kompella, U.B., and Ambati, B.K. Nanoparticles prolong retention of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis.  Invest. Ophthalmol. Vis. Sci.  48:2030-2036 (2007).

35. Marra, M., Gukasyan, H.J., Raghava, S., and Kompella, U.B.* 2nd ophthalmic drug development and delivery summit San Diego, CA USA, 19-20 September 2006. Expert Opin. Drug Deliv. 4(1): 77-85 (2007).

36. Kompella, U.B.*, Sundaram, S., Raghava, S., and Escobar, E. Functionalizations enhance nanoparticles delivery in a novel bovine ex vivo eye model. Mol. Vis. 12: 1185-1198 (2006).

37. Cheruvu, N.P.S. and Kompella, U.B.* Bovine and porcine transscleral solute transport: Influence of lipophilicity and choroid-Bruch’s layer. Invest. Ophthalmol. Vis. Sci. 47(10):4513-4522 (2006).

38. Margalit, E., Kugler, L.J., Brum, M.V., Meza, J.L., Kompella, U.B., Escobar, E., and Christensen, G.R. The safety of intraocular ketorolac in rabbits. Invest. Ophthalmol. Vis. Sci. 47(5):2093-2099 (2006).

39. Yun, M., Smyth, H., Kompella, U.B.* Particle engineering for sustained pulmonary drug delivery. Business Briefings: Drug Delivery 2006.

40. Amrite, A., Ayalasomayajula, S.P., Cheruvu, N.P.S., Kompella, U.B.* Single periocular injection of celecoxib-PLGA microparticles reduces diabetes induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47(3):1149-1160 (2006).

41. Hammond, M. and Kompella, U.B.* Nanotechnology and nanoparticles: Clinical, ethical, and regulatory issues. In: Nanoparticle Technology for Drug Delivery. Ram B. Gupta and Uday B. Kompella (Eds.). Marcel Dekker, Inc. New York. Pp. 381-395 (2006).

42. Amrite, A. and Kompella, U.B.* Nanoparticles for ocular drug delivery. In: Nanoparticle Technologies for Drug Delivery. Ram B. Gupta and Uday B. Kompella (Eds.). Marcel Dekker, Inc. New York. Pp. 319-360 (2006).

43. Amrite, A. and Kompella, U.B.* Disposition of periocularly administered nanoparticles and microparticles. J. Pharm. Pharmacol. 57(12):1553-1563 (2005).

44. Bandi, N., Ayalasomayajula, S.P., Iwakawa, J., Cheng, P-W, and Kompella, U.B.* Intratracheal budesonide microparticles sustain respiratory delivery of budesonide and reduce oxidative stress, VEGF expression and vascular leakage in a benzo(a)pyrene-fed mouse model for lung tumors. J. Pharm. Pharmacol. 57(7):851-860 (2005).

45. Dhanda, D.S. and Kompella, U.B. * Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) for Pulmonary Drug Delivery: CMC Issues. Clin. Res. Reg. Affairs 22(1):31-55 (2005).

46. Dhanda, D.S., Leopold, D., Frey II, W.H., and Kompella, U.B.* Approaches for the deposition of drugs in the human olfactory epithelium. Drug Del. Technol. 5(4)64-72 (2005).

47. Ayalasomayajula, S. P. and Kompella, U. B.* Subconjunctival administration of celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511:493-498 (2005).

48. Kompella, U.B.* Graduate education in the era of nanotechnology, nanomedicine, and pharmacogenomics. Controlled Release Society News Letter, 22(1):22-32 (2005).

49. Raghava, S., Hammond, M., and Kompella, U.B.* Periocular routes for retinal drug delivery. Exp. Opinion Drug Del. 1:99-114 (2004).

50. Ayalsomayajula, S.P. and Kompella, U.B. * Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 21(10):1797-1804 (2004).

51. Sundaram, S., Bontha, S. S., and Kompella, U.B.* Respiratory delivery of deslorelin, a peptide drug. Am. Pharm. Rev. 7(5):130-139 (2004).

52. Bandi, N., Wei, W., Roberts, C.B., Kotra, L.P., and Kompella, U.B.* Preparation of budesonide- and indomethacin- hydroxypropyl-?-cyclodextrin (HP?CD) complexes using an organic-solvent-free, single-step supercritical fluid process. Eur. J. Pharm. Sci. 23(2): 159-168 (2004).

53. Ayalasomayajula, S.P., Amrite, A., and Kompella, U.B.* Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin-E2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 498:275-278 (2004).

54. Koushik, K., Dhada, D.S., Cheruvu, N.P.S., and Kompella, U.B.* Pulmonary delivery of deslorelin: Large porous PLGA particles and HP?CD complexes. Pharm. Res. 21(7):1119-1126 (2004).

55. Koushik, K. and Kompella, U.B.* Transport of deslirelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J. Pharm. Pharmacol. 56(7):861-868 (2004).

56. Amrite, A.A., Cheruvu, N.P.S., Sundaram, S., Aravalli, R.N., Cheng, P-W, and Kompella, U.B.* Lung Gene Therapy: Clinical and Regulatory Issues. Clin. Res. Reg. Affairs 21:1-28 (2004).

57. Koushik, K., Bandi, N., and Kompella, U.B.* Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm. Res. 21:1034-1046 (2004).

58. Sunkara, G., Ayalasomayajula, S.P., Cheruku, R.S., Vennerstrom, J.L., DeRuiter, J., and Kompella, U.B.* Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J. Pharm. Pharmacol. 56:351-358 (2004).

59. Koushik, K. and Kompella, U.B.* Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical CO2 process. Pharm Res. 21:524-535 (2004).

60. Koushik, K. and Kompella, U.B. * Particle and device engineering for inhalation drug delivery. Drug Del. Technol. 4: 40-50 (2004).

61. Amrite, A. and Kompella, U.B.* Eye cancers. xPharm (2004). Executive editors: S.J. Enna and David B. Bylund; Elsevier Inc., New York. http://www.xpharm.com/citation?Article ID=913 (Online peer-reviewed disease and pharmacology database).

62. Ha, E., Ganguly, M., Li, X., Jasti, B.R., and Kompella, U.B.* Delivery of peptide and protein drugs. In: Theory and Practice of Contemporary Pharmaceutics, Tapash K. Ghosh and Bhaskara R. Jasti (Eds.), Taylor & Francis, pp. 525-547 (2004).

63. Mayo, A. and Kompella, U.B. * Supercritical fluid technology in pharmaceutical research. In: Encyclopedia of Pharmaceutical Technology. James Swarbrick (Ed.). Marcek Dekker, Inc., New York, pp, 1-17, 2004.

64. Bandi, N., Gupta, R.B., Roberts, C.B., and Kompella, U.B.* Formulation of controlled release drug delivery systems. In: Drug Delivery and Supercritical Fluid Technology. Marcel Dekker, Inc. P.York, U.B. Kompella, and B. Shekunov (Eds). Marcel Dekker, Inc., New York. 367-410, 2004.

65. Kompella, U.B.* Reflections of Uday B. Kompella, PhD, Student Chapter Faculty Advisor. AAPS Newsmagazine. Page 41, July 2004.

Publications - 2003 and Earlier

66. Aukunuru, J.V., Ayalasomayajula, S.P., and Kompella, U.B.* A nanoparticle formulation enhances the delivery and activity of a VEGF antisense oligonucleotide in human retinal pigment epithelial (ARPE-19) cells. J. Pharm. Pharmacol. 55(9):1199-1206 (2003).

67. Cheruvu, N.P.S., Ayalasomayajula, S.P., and Kompella, U.B.* Retinal delivery of sodium fluorescein, budesonide, and celecoxib following subconjunctival injection. Drug Del. Technol. 3(6): 62-67(2003).

68. Amrite, A. and Kompella, U.B.* Ocular distribution of intact nano- and microparticles following subconjunctival and systemic routes of administration. Drug Del. Tech. 3:62-67 (2003).

69. Koushik, K., Sunkara, S., Gwilt, P., and Kompella, U.B.* Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm. Res. 20:779-787 (2003).

70. Kompella, U.B.*, Bandi, N., and Ayalasomayajula, S.P. Subconjunctival nano- and micro-particles for sustained retinal delivery of budesonide, a glucocorticoid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44: 1192-1201 (2003).

71. Ayalasomayajula, S.P. and Kompella, U.B.* Celecoxib, a selective COX-2 inhibitor, inhibits retinal VEGF expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458:283-289 (2003).

72. Sunkara, G. and Kompella, U.B.* Membrane transport processes in the eye. In: Ocular Drug Delivery Systems. Mitra A.K. (Ed.), Marcel Dekker, Inc. 2nd Edition, pp 13-58, 2003.

73. Wenzel, J.G.W., Sree Balaji, K.S., Koushik, K., Navarre, C., Duran, S.H., Rahe, C.H., and Kompella, U.B.* Pluronic® F127 gel formulation of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J. Control. Rel. 85:51-59 (2002).

74. Zhang, L., Parsons, D.L., Navarre, C.B., and Kompella, U.B.* Development and in vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J. Control. Rel. 85:73-81 (2002).

75. Martin, T.M., Bandi, N., Schulz, R., Roberts, C., and Kompella, U.B. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech. 3(3) article 18 (2002).

76. Ayalasomayajula, S.P. and Kompella, U.B.* Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur. J. Pharmacol. 449:213-220 (2002).

77. Bandi, N. and Kompella, U.B.* Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (calu-1). Eur. J. Pharmacol. 437(2): 9-17 (2002).

78. Sunkara G. and Kompella, U.B.* Drug delivery applications of supercritical fluid technology. Drug Del. Technol. 2:44-50 (2002).

79. Aukunuru, J.V. and Kompella, U.B.* In vitro delivery of nano- and micro-particles to retinal pigment epithelial (RPE) cells. Drug Del. Technol. 2:50-57 (2002).

80. Aukunuru, J.V., Sunkara, G., Ayalasomayajula, S.P., DeRuiter, J., Clark, R.C., and Kompella, U.B.* A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm. Res. 19:278-285 (2002).

81. Koushik, K.N., Bandi, N., and Kompella, U.B.* Interaction of [D-Trp6-Des-Gly10]LHRH ethylamide and hydroxypropyl ?-cyclodextrin (HP?CD): Thermodynamics of interaction and protection from degradation by ?-chymotrypsin. Pharm. Dev. Technol. 6:595-606 (2001).

82. Kompella, U.B.*, Bandi, N., and Ayalasomayajula, S.P. Poly(lactic acid) nanoparticles for sustained release of budesonide. Drug Del. Technol. 1(1), 28-34(2001).

83. Bandi, N. and Kompella, U.B.* Budesonide reduces vascular endothelial growth factor (VEGF) secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 425:109-116 (2001).

84. Aukunru, J.V. and Kompella, U.B.* Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. 18:565-572 (2001).

85. Kompella, U.B.* and Koushik, K. Preparation of drug delivery systems using supercritical fluid technology. Crit. Rev. Ther. Drug Carr. Syst. 18:173-199 (2001).

86. Kompella, U.B. and Lee, V.H.L. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations,  Adv. Drug Del. Rev. 46:211-245 (2001).

87. Sunkara, G. and Kompella, U.B.* Controlled Release of Bioactive Materials – 28th International Symposium. Carbohydrate drug carriers: Cyclodextrins and chitosans. IDrugs, 4(9):1014-1016 (2001).

88. Sunkara, G., DeRuiter, J., Clark, C.R., and Kompella, U.B.* In-vitro hydrolysis, permeability, and ocular uptake of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor intended for ocular complications of diabetes. J. Pharm. Pharmacol. 52:1113-1122 (2000).

89. Aukunuru, J.V., Kompella, U.B., and Betageri, G.V. Simultaneous high-performance liquid chromatographic analysis of acetaminophen, salicylamide, phenyltoloxamine and related products. J. Liq. Chrom. & Rel. Technol. 23:565-578 (2000).

90. Kompella, U.B.*, Sunkara, G., Thomas, E., Clark, C.R., and DeRuiter, J. Corneal and Conjunctival Permeability of Novel Aldose Reductase Inhibitors: N-\[[4-(Benzoylamino)phenyl]sulfonyl]glycines and N-Benzoyl-N-phenyl Glycines. J. Pharm. Pharmacol. 51:921-927 (1999).

91. Sunkara, G., Navarre, C.B., and Kompella, U.B.* Influence of pH and temperature on kinetics of ceftiofur degradation in aqueous solutions. J. Pharm. Pharmacol. 51:249-255 (1999).

92. Navarre, C.B., Zhang, L., Sunkara, G., Duran, S.H., and Kompella, U.B. Ceftiofur distribution in plasma and joint fluid following regional limb injection in cattle. J. Vet. Pharmacol. Ther. 22:13-19 (1999).

93. Kompella, U.B.*, Aukunuru, J.V., and Betageri, G.V. Effect of neutral liposomes on corneal and conjunctival transport of didanosine. Drug Delivery 6:9-14 (1999).

94. Ayalasomayajula, S.P. and Kompella, U.B.* Drug efflux pumps: Challenges and opportunities. 14-18 November 1999, New Orleans, USA. American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part IV). IDrugs 3(2):148-149 (2000).

95. Koushik, K. and Kompella, U.B.* Particle engineering and modeling techniques for inhalation delivery. 14-18 November 1999, New Orleans, USA. American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part V). Investigational Drugs Weekly Highlights, 49:44-46 (1999). 

96. Aukunuru, J.V. and Kompella, U.B.* American Association of Pharmaceutical Scientists - Annual Meeting and Exposition (Part VI). Recent advances in particulate and implant drug delivery systems. 14-18 November 1999, New Orleans, USA. Investigational Drugs Weekly Highlights, 49:58-61 (1999).

97. Kompella, U.B.* Protein drug delivery. In: Biopharmaceutical Drug Design and Development, Wu-Pong, S. and Rojanasakul, Y. (Eds.), Humana Press, pp. 239-274, 1999.

98. Kompella, U.B. and Lee, V.H.L.  Barriers to drug transport in ocular epithelia, in:  Transport Processes in Pharmaceutical Systems. G.L. Amidon, P.I. Lee, and and E.M. Topp (eds.) Marcel Dekker, Inc., New York, pp. 317-376, 1999.

99. Kompella, U.B.* "Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development, Mathiowitz, E.,Chickering, D.E., III, and Lehr, C-M. (eds), Marcel Dekker, Inc., New York, 1999". Review for Doody Publishing Company (1999). Book-review.

100. Mathison, S., Nagilla, R., and Kompella, U.B.* Nasal route for direct delivery of solutes to brain. Fact or Fiction? J. Drug Targeting 5:415-441(1998).

101. Kompella, U.B.*, Katragadda, A.K., Aukunuru, J.V., and Betageri, G.V. Effect of liposomal charge on stavudine transport across cornea and conjunctiva. Pharm. Pharmacol. Commun. 4:339-343 (1998).

102. Dani, B.A. and Kompella, U.B.* Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2, Drug Dev. Ind. Pharm. 24(1):11-17 (1998).

103. Kompella, U.B.* Drug delivery applications of supercritical fluid technology. 15-19 November 1998, San Francisco, USA. American Association of Pharmaceutical Scientists Annual Meeting and Exposition (Part II). IDrugs, 2(1):33-34 (1999).

104. Kompella, U.B.* Disposition of non-viral gene delivery systems and oligonucleotides. 15-19 November 1998, San Francisco, USA. American Association of Pharmaceutical Scientists Annual Meeting and Exposition (Part V). IDrugs, 2(1):31-32 (1999).

105. Kompella, U.B.* and Dani, B.A. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit conjunctiva, J. Ocular Pharmacol. Ther. 13(2):163-170 (1997).

106. Kompella, U.B.* and Dani, B.A. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit nasal tissue, Life Sci., 58:2201-2207 (1996).

107. Kompella, U.B., Kim, K.J., Shiue, M.H.I., and Lee, V.H.L., Cyclic AMP modulation of active ion transport in the pigmented rabbit conjunctiva, J. Ocular Pharmacol. Ther. 12:281-287 (1996).

108. Hosoya, K., Kompella, U.B., Kim, K.J., and Lee, V.H.L., Contribution of Na+-glucose cotransport to the short-circuit current in the pigmented rabbit conjunctiva, Curr. Eye Res. 15:447-451 (1996).

109. Kompella, U.B., Kim, K.J., and Lee, V.H.L., Possible existence of Na+-coupled amino acid transport in the pigmented rabbit conjunctiva, Life Sci. 57:1427-1431 (1995).

110. Kompella, U.B., Kim, K.J., and Lee, V.H.L. Active secretion of chloride across the pigmented rabbit conjunctiva, Curr. Eye Res. 12:1041-1048 (1993).

111. Lee, Y.H., Kompella, U.B., and Lee, V.H.L. Systemic absorption pathways of topically applied beta-adrenergic antagonists in the pigmented rabbit, Exp. Eye Res. 57:341-349 (1993).

112. Kompella, U.B. and Lee, V.H.L. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations,  Adv. Drug Del. Rev. 8:115-162 (1992).

113. Lee, V.H.L. and Kompella, U.B., “Therapeutic Monoclonal Antibodies, Borrebaeck, C.A.K. and Larrick, J.W., Stockton Press, New York, 1990”, J. Control. Rel., 18:280-281 (1992). Book-review.

114. Lee, V.H.L., Yamamoto, A., and Kompella, U.B., Mucosal penetration enhancers for facilitation of peptide and protein drug absorption, CRC Crit. Rev. Drug Carrier Sys. 8:91-192 (1991).

115. Kompella, U.B. and Lee, V.H.L.  Pharmacokinetics of peptide and protein drugs, in:  Peptide and Protein Drug Delivery, V.H.L. Lee (ed.), Marcel Dekker, Inc., New York, pp. 391-484, 1991.

116. Nagappa, A.N., Kompella, U.B., Shankar, S., Mitra, S., and Srivastava, R.C., Liquid membrane phenomenon in the biological action of gonadal steroid hormones, Ind. J. Biochem & Biophys. 25:350-355 (1988).

Books Edited

Supercritical fluid technology for drug product development

books.google.com
Peter York, Uday B. Kompella, Boris Y. Shekunov - 2004 - 666 pages - Google eBook - Preview

Interconnecting the fundamentals of supercritical fluid (SCF) technologies, their current and anticipated utility in drug delivery, and process engineering advances from related methodological domains and pharmaceutical applications, this ...

Nanoparticle technology for drug delivery

books.google.com
Ram B. Gupta, Uday B. Kompella - 2006 - 403 pages - No preview

Nanoparticles, products of nanotechnology, are of increasing interest to the pharmaceutical community.

Drug Product Development for the Back of the Eye

books.google.com
Uday B. Kompella, Henry F. Edelhauser - 2011 - 522 pages - No preview

Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and ...